Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial

Bibliographic Details
Main Authors:	Roger Owen, John Jones, David Meads, David A Cairns, Christopher Parrish, Gordon Cook, Neil Rabin, Matthew Jenner, Martin Kaiser, Kevin Boyd, Graham Jackson, Catherine Olivier, Amy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, Anna Hockaday, Jennifer Bird, Stella Bowcock, Ruth de Tute, Hayley Gardner, Bryony Dawkins, Rowena Henderson, Phillip Best, Bhuvan Kishore, Mark Drayson
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-06-01
Series:	BMJ Open
Online Access:	https://bmjopen.bmj.com/content/12/6/e056147.full

Similar Items

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial
by: Roger Owen, et al.
Published: (2022-11-01)

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI TrialResearch in context
by: John R. Jones, et al.
Published: (2023-08-01)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
by: Shah, V, et al.
Published: (2020)

The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
by: Alina Striha, et al.
Published: (2018-03-01)

Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results
by: Holger W. Auner, et al.
Published: (2022-04-01)

Molecular profiling in myeloma
by: Charlotte Pawlyn, et al.
Published: (2018-06-01)

Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT
by: Mark T Drayson, et al.
Published: (2019-11-01)

Induction Treatment in Transplant-eligible Multiple Myeloma
by: J. Quinn, et al.
Published: (2021-05-01)

P11: IXAZOMIB WITH CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MYELOMA: MUKEIGHT PHASE II RANDOMISED CONTROLLED TRIAL RESULTS
by: H Auner, et al.
Published: (2022-04-01)

Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients
by: Aikaterini Panopoulou, et al.
Published: (2023-02-01)

The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma
by: Arthur Bobin, et al.
Published: (2020-05-01)

Myeloma and leukaemia trials.
by: Peto, R
Published: (1972)

Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations
by: Amelie Boquoi, et al.
Published: (2022-04-01)

How I manage frontline transplant-eligible multiple myeloma in Italy
by: Vittorio Montefusco, et al.
Published: (2020-09-01)

Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial
by: Stella Bowcock, et al.
Published: (2023-06-01)

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
by: Stefania Oliva, et al.
Published: (2021-06-01)

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
by: Elena Zamagni, et al.
Published: (2020-12-01)

Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia
by: Qerimi V, et al.
Published: (2018-06-01)

Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs
by: Kolovos, S, et al.
Published: (2019)

Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
by: H. V. Giles, et al.
Published: (2024-03-01)

PB1993: MULTIPLE MYELOMA BRAZILIAN REGISTER- HOW ABOUT THE TRANSPLANT ELIGIBLE PATIENTS?
by: E. Crusoe, et al.
Published: (2022-06-01)

30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
by: Aurelia Chacon, et al.
Published: (2023-03-01)

The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review
by: Hira Mian, et al.
Published: (2023-01-01)

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
by: Sarah A. Bird, et al.
Published: (2020-05-01)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
by: Laura Rosiñol, et al.
Published: (2023-11-01)

Recent updates on CAR T clinical trials for multiple myeloma
by: Quande Lin, et al.
Published: (2019-11-01)

PB2091: DISPARITIES IN ENROLMENT INTO MULTIPLE MYELOMA CLINICAL TRIALS BY SOCIOECONOMIC DEPRIVATION
by: Amrutha Sridhar, et al.
Published: (2023-08-01)

Elective vs non-elective hospital admissions by patients with multiple myeloma in England 2014 - 2018
by: Ramasamy, K, et al.
Published: (2018)

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group
by: Anu Partanen, et al.
Published: (2024-02-01)

P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS
by: Tereza Popková, et al.
Published: (2023-08-01)

Impact of Comorbidities on Health-related Quality of Life in Nontransplant Eligible Patients With Newly Diagnosed Multiple Myeloma
by: M. Christine Bennink, et al.
Published: (2022-07-01)

Challenges in designing and running smouldering myeloma interventional clinical trials
by: Catherine Lecat, et al.
Published: (2024-04-01)

Multiple Myeloma in 2023 Ways: From Trials to Real Life
by: Manlio Fazio, et al.
Published: (2023-11-01)

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
by: Clive Henry Buckle, et al.
Published: (2012-01-01)

PB2109: PROGNOSTIC VALUE OF MYC STRUCTURAL VARIATIONS IDENTIFIED BY FISH IN TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
by: Ines Dos Santos Marques, et al.
Published: (2023-08-01)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
by: Ajay K. Nooka, et al.
Published: (2022-04-01)

Welding fumes exposure, body mass index and duration of smoking decrease physical fi tness among welders
by: Rudy Wahyu Perdana, et al.
Published: (2012-09-01)

Welding fumes exposure, body mass index and duration of smoking decrease physical fi tness among welders
by: Rudy Wahyu Perdana, et al.
Published: (2012-09-01)

Myeloma /
by: 455001 Tanner, Jerome E., et al.
Published: (2008)

Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study
by: Ilaria J Chicca, et al.
Published: (2020-12-01)